D. V. Byrikhina

Systematic Approach to Production Technology Development for Therapeutic Proteins (Using Insulin–Glargine as an Example)

D. Gusarov, D. V. Byrikhina, F. Izhaeva, 2015, Pharmaceutical Chemistry Journal.

Comparison of different technologies for producing recombinant adeno-associated virus on a laboratory scale

D. V. Byrikhina, D. Shcheblyakov, I. Esmagambetov, 2021 .

Physicochemical Properties, Toxicity, and Specific Activity of a Follitropin Alpha Biosimilar

M. Serebryakova, O. Proskurina, D. V. Byrikhina, 2017, Pharmaceutical Chemistry Journal.

rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19

A. Gintsburg, D. Logunov, B. Naroditsky, 2023, Frontiers in Immunology.

Comparison of different technologies for producing recombinant adeno-associated virus on a laboratory scale

D. V. Byrikhina, I. Esmagambetov, E. I. Ryabova, 2021, BIOpreparations. Prevention, Diagnosis, Treatment.